Apixaban

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Non-valvular Atrial Fibrillation

Conditions

Non-valvular Atrial Fibrillation

Trial Timeline

Oct 15, 2013 → Jan 20, 2016

NCT ID

NCT01884350

About Apixaban

Apixaban is a approved stage product being developed by Bristol Myers Squibb for Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT01884350. Target conditions include Non-valvular Atrial Fibrillation.

What happened to similar drugs?

1 of 2 similar drugs in Non-valvular Atrial Fibrillation were approved

Approved (1) Terminated (0) Active (1)

✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved

🔄DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05187286	Pre-clinical	Active	—	—	—
NCT03594045	Phase 2	Terminated	Dec 18, 2018	Oct 30, 2019	Heparin-induced Thrombocytopenia
NCT02958969	Approved	Completed	Feb 28, 2018	Nov 19, 2019	Venous Thromboembolism
NCT03456648	Phase 2	Completed	Sep 25, 2016	Aug 24, 2018	ESRD
NCT02714855	Pre-clinical	Completed	Oct 1, 2015	Dec 1, 2016	Anticoagulation
NCT02345343	Pre-clinical	Completed	May 4, 2015	Oct 7, 2015	Deep Vein Thrombosis
NCT01885585	Pre-clinical	Completed	Jul 1, 2014	May 1, 2015	Venous Thromboembolism
NCT02153424	Pre-clinical	Withdrawn	Apr 1, 2014	Nov 1, 2015	Non-valvular Atrial Fibrillation (NVAF)
NCT02101112	Phase 1	Completed	Mar 1, 2014	May 1, 2014	Thrombosis
NCT01884350	Approved	Completed	Oct 15, 2013	Jan 20, 2016	Non-valvular Atrial Fibrillation
NCT01885598	Pre-clinical	Completed	Jul 10, 2013	Sep 29, 2017	NonValvular Atrial Fibrillation
NCT00252005	Phase 2	Completed	Nov 1, 2005	Feb 1, 2007	Deep-Vein Thrombosis

Competing Products

17 competing products in Non-valvular Atrial Fibrillation

See all competitors

Product	Company	Stage	Hype Score
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg	Daiichi Sankyo	Phase 3	40
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin	Daiichi Sankyo	Approved	39
Edoxaban	Daiichi Sankyo	Pre-clinical	26
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Apixaban + Warfarin	Pfizer	Pre-clinical	26
Warfarin + Apixaban	Pfizer	Pre-clinical	26
Apixaban	Bristol Myers Squibb	Pre-clinical	18
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban(Xarelto,BAY 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto,Bay 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Warfarin	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY-597939) + VKAs	Bayer	Pre-clinical	23
Non-VKA Oral Anticoagulants (NOAC)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto_ BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan)	Bayer	Pre-clinical	15